^
    Back
    Association details:
    Biomarker:MDM2 amplification
    Cancer:Solid Tumor
    Drug:milademetan (RAIN-32) (MDM2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Milademetan in Advanced/Metastatic Solid Tumors

    Excerpt:
    ...- MDM2 amplification:...
    Trial ID:
    MANTRA-2
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

    Excerpt:
    ...- Participants with certain tumor types such as those with high prevalence of MDM2 amplification or overexpression (eg, well-differentiated [WD]/dedifferentiated [DD] liposarcoma) may be preferentially enrolled in Part 1....
    Trial ID:
    NCT01877382
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma(WD/DD LPS), solid tumors (ST) and lymphomas (L).

    Published date:
    05/16/2018
    Excerpt:
    Objective responses and durable SD were seen in MDM2 amplified ST and DDLPS…
    DOI:
    10.1200/JCO.2018.36.15_suppl.11514
    Trial ID:
    NCT01877382